scholarly journals Benefit of adjuvant chemotherapy in node-negative T1a versus T1b and T1c triple-negative breast cancer

2022 ◽  
Author(s):  
Genevieve A. Fasano ◽  
Solange Bayard ◽  
Yalei Chen ◽  
Leticia Varella ◽  
Tessa Cigler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Node Negative

Outcomes with neoadjuvant versus adjuvant chemotherapy for T1-2 node negative triple negative breast cancer.

2015 ◽  
Vol 33 (15_suppl) ◽  
pp. 1092-1092 ◽  
Author(s):  
Priyanka Sharma ◽  
Bruce F. Kimler ◽  
Jennifer R. Klemp ◽  
Claire Ward ◽  
Carol Sue Connor ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Node Negative

Adjuvant chemotherapy in small node-negative triple-negative breast cancer

2020 ◽  
Vol 135 ◽  
pp. 66-74
Author(s):  
Tessa G. Steenbruggen ◽  
Erik van Werkhoven ◽  
Mette S. van Ramshorst ◽  
Vincent O. Dezentjé ◽  
Marleen Kok ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Node Negative

scholarly journals Benefit of Adjuvant Chemotherapy in Node-Negative T1a Versus T1b and T1c Triple Negative Breast Cancer

2021 ◽  
Author(s):  
Genevieve A Fasano ◽  
Solange Bayard ◽  
Yalei Chen ◽  
Leticia Varella ◽  
Tessa Cigler ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Tumor Size ◽  
Triple Negative ◽  
The United States ◽  
Adjuvant Radiation ◽  
Node Negative ◽  
Cancer Network

Abstract Purpose: National Comprehensive Cancer Network guidelines recommend delivery of adjuvant chemotherapy in node-negative triple negative breast cancer (TNBC) if the tumor is > 1 cm and consideration of adjuvant chemotherapy for T1b but not T1a disease. These recommendations are based upon sparse data regarding the role of adjuvant chemotherapy in T1a and T1b node-negative TNBC. Our objective was to clarify the benefits of chemotherapy for patients with T1N0 TNBC, stratified by tumor size.Methods: We performed a retrospective analysis of survival outcomes in an IRB-approved prospectively-maintained database of TNBC patients treated at two academic institutions in the United States from 1999-2018. Primary tumor size, histology, and nodal status were based upon definitive surgical pathology. Mean follow-up was 5.3 years.Results: 756 TNBC cases were analyzed; 258 T1N0 TNBC patients were identified. Adjuvant chemotherapy was delivered to 30.5% of T1a, 64.7% T1b, and 83.9% T1c (p < 0.0001). Factors associated with delivery of adjuvant chemotherapy were age, histology, high-grade disease, and postoperative adjuvant radiation therapy. At a mean follow-up of 5.3 years, increase in overall survival was associated with use of chemotherapy in patients with T1c disease (93.2% v. 75.2% p = 0.008) but not in those with T1a (100% v. 100% p = 0.3778) or T1b (100% v. 95.8% p = 0.2362) disease.Conclusion: Our data support current guidelines indicating benefit from adjuvant chemotherapy in node-negative TNBC associated with T1c tumors but excellent outcomes were observed in cases of T1a and T1b disease, regardless of whether adjuvant chemotherapy was delivered.

scholarly journals The effect of adjuvant chemotherapy on survival in Korean patients with node negative T1c, triple negative breast cancer

PLoS ONE ◽  
2018 ◽  
Vol 13 (5) ◽  
pp. e0197523 ◽  
Author(s):  
Seung Taek Lim ◽  
Chan Heun Park ◽  
Sung Yong Kim ◽  
Seok Jin Nam ◽  
Eun Young Kang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Node Negative ◽  
Korean Patients

scholarly journals The Survival Outcomes of T1aN0M0 Triple-Negative Breast Cancer With Adjuvant Chemotherapy

2020 ◽  
Vol 10 ◽  
Author(s):  
Wen-Fen Fu ◽  
Qing-Xia Chen ◽  
Xiao-Xiao Wang ◽  
Jie Zhang ◽  
Chuan-Gui Song
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Survival Outcomes

PD-L1 expression and TOP3A mutation as prognostic factors for adjuvant chemotherapy in triple negative breast cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. 541-541
Author(s):  
Xue Wang ◽  
Peng Yuan ◽  
Feng Du ◽  
Lina Cui ◽  
Fangchao Zheng ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Disease Free Survival ◽  
Genetic Alterations ◽  
Functional Enrichment ◽  
Pathway Enrichment Analysis ◽  
Genetic Characteristics ◽  
Significant Difference

541 Background: Triple negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer that is markedly heterogeneous and lacks specific targets. The aim of this study is to explore potential predictors and therapeutic targets based on clinical and genetic characteristics. Methods: 138 patients with triple-negative breast cancer after surgical treatment were 1:1 randomly assigned to the paclitaxel combined with carboplatin (TCb) group or the epirubicin combined with cyclophosphamide sequential paclitaxel (EC-T) adjuvant chemotherapy group. PD-L1 was retrospectively analyzed by surgically resected specimens, and 733 cancer-related genes were detected by NGS. Pathway enrichment analysis was performed using DAVID for functional enrichment genetic alterations. Cox regression models and Kaplan-Meier were used to evaluate disease-free survival (DFS). Results: In this study, there was no significant difference in DFS between the TCb and EC-T groups. 31 (22.5%) of 138 TNBC patients were positive for PD-L1 expression, including 15 (10.9%) patients positive for PD-L1 in tumor cells (TCs) and 29 (21.0%) patients positive for PD-L1 in tumor-infiltrating immune cells (TICs). Patients with positive PD-L1 expression, either in TCs or TICs, achieved better DFS [HR=0.13 (95% CI: 0.02-0.93), p=0.016], the difference was also shown in the EC-T group [HR=0 (95% CI: 0- inf), p=0.037], but not in the TCb group [HR=0 (95% CI: 0.04-2.1), p=0.189]. In addition, we identified 7 patients with mutations in DNA topoisomerase IIIα(TOP3A), a homologous recombination (HR)-related gene, and patients with mutations in this gene had worse DFS than those without mutations [HR=4]. However, there was no statistically significant association between BRCA mutation and response to either therapeutic regimens. Conclusions: In this TNBC patient population, immunohistochemistry (IHC) and NGS analyses identified potential prognostic markers. PD-L1 positive and TOP3A mutation were significantly associated with early triple-negative breast cancer prognosis.

scholarly journals Effects of adjuvant chemotherapy on recurrence rate in T1abN0M0 triple-negative breast cancer: A meta-analysis

2020 ◽  
Vol 25 ◽  
pp. 100211
Author(s):  
Zijian Yang ◽  
Yonghua Chen ◽  
Xiaoling Liu ◽  
Junwei Cui ◽  
Yibing Hu ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Adjuvant Chemotherapy ◽  
Recurrence Rate ◽  
Triple Negative Breast Cancer ◽  
Triple Negative ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document